Ursolic acid (Prunol) is a natural triterpenoid carboxylic acid compound with preventive and anticancer activities. Ursolic acid also has proteasome agonist activity, EC50=14 μmol/L.
Usnic acid is a lichen secondary metabolite with a unique dibenzofuran skeleton. Usnic acid has excellent anti-cancer and antibacterial properties. Usnic acid significantly inhibited ranKL-mediated osteoclast formation and function by decreasing transcription and translational expression of NFATc1.
USP7-IN-8 is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in the Ub-Rho110 assay.USP7-IN-8 is inactive against USP47 and USP5.USP7-IN-8 has anticancer effects.
USP7-IN-8 is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in the Ub-Rho110 assay.USP7-IN-8 is inactive against USP47 and USP5.USP7-IN-8 has anticancer effects.
USP7-IN-8 is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in the Ub-Rho110 assay.USP7-IN-8 is inactive against USP47 and USP5.USP7-IN-8 has anticancer effects.
USP7-IN-8 is a selective ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 1.4 μM in the Ub-Rho110 assay.USP7-IN-8 is inactive against USP47 and USP5.USP7-IN-8 has anticancer effects.
USP7/USP47 inhibitor is a selective ubiquitin-specific protease 7/47 (USP7/USP47) inhibitor, with EC50s of 0.42 μM and 1.0 μM, respectively.
USP7/USP47 inhibitor is a selective ubiquitin-specific protease 7/47 (USP7/USP47) inhibitor, with EC50s of 0.42 μM and 1.0 μM, respectively.
Ustekinumab is a human monoclonal antibody that targets IL12 and IL23, natural proteins that regulate the immune system and immune-mediated inflammatory diseases.
Ustekinumab is a human monoclonal antibody that targets IL12 and IL23, natural proteins that regulate the immune system and immune-mediated inflammatory diseases.